Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

INVO Bioscience stock price, quote, forecast and news

INVO
US44984F4019

Price

0.69
Today +/-
-0.01
Today %
-1.79 %
P

INVO Bioscience stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the INVO Bioscience stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the INVO Bioscience stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the INVO Bioscience stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze INVO Bioscience's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

INVO Bioscience Stock Price History

DateINVO Bioscience Price
9/26/20240.69 undefined
9/25/20240.70 undefined
9/24/20240.69 undefined
9/23/20240.69 undefined
9/20/20240.70 undefined
9/19/20240.69 undefined
9/18/20240.69 undefined
9/17/20240.68 undefined
9/16/20240.70 undefined
9/13/20240.71 undefined
9/12/20240.70 undefined
9/11/20240.70 undefined
9/10/20240.68 undefined
9/9/20240.73 undefined
9/6/20240.76 undefined
9/5/20240.79 undefined
9/4/20240.77 undefined
9/3/20240.79 undefined
8/30/20240.80 undefined
8/29/20240.78 undefined

INVO Bioscience Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into INVO Bioscience, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by INVO Bioscience from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects INVO Bioscience’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of INVO Bioscience. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into INVO Bioscience’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing INVO Bioscience’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on INVO Bioscience’s growth potential.

INVO Bioscience Revenue, EBIT and net profit per share

DateINVO Bioscience RevenueINVO Bioscience EBITINVO Bioscience Net Income
2029e126.72 M undefined0 undefined0 undefined
2028e94.91 M undefined30.65 M undefined0 undefined
2027e66.91 M undefined15.36 M undefined0 undefined
2026e46.23 M undefined5.92 M undefined0 undefined
2025e21.39 M undefined-2.66 M undefined0 undefined
2024e8.61 M undefined-7.3 M undefined-797,640 undefined
20233.02 M undefined-6.77 M undefined-8.03 M undefined
2022820,000 undefined-10.63 M undefined-10.89 M undefined
20214.16 M undefined-5.22 M undefined-6.65 M undefined
20201.04 M undefined-5.51 M undefined-8.35 M undefined
20191.48 M undefined-1.79 M undefined-2.17 M undefined
2018490,000 undefined-2.63 M undefined-3.08 M undefined
2017280,000 undefined-640,000 undefined-700,000 undefined
201650,000 undefined-2.11 M undefined-2.12 M undefined
201510,000 undefined-600,000 undefined-4.96 M undefined
201420,000 undefined-1.68 M undefined-1.73 M undefined
201330,000 undefined-610,000 undefined-760,000 undefined
201260,000 undefined-550,000 undefined-670,000 undefined
201170,000 undefined-700,000 undefined-800,000 undefined
201070,000 undefined-1.52 M undefined-150,000 undefined
200960,000 undefined-1.84 M undefined-4.66 M undefined
200840,000 undefined-1.86 M undefined-1.87 M undefined
20070 undefined-210,000 undefined-210,000 undefined
20060 undefined-10,000 undefined-10,000 undefined

INVO Bioscience Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000000000000011403821466694126
---------------300.00--166.67162.50119.0543.4842.4234.04
-------------100.00-100.00-33.33------
000000000000010401000000
00-1-1-1000-10-20-2-1-5-5-10-6-7-2515300
--------------100.00-500.00-125.00--200.00-87.50-9.5210.8722.7331.91-
00-1-40000-1-4-20-3-2-8-6-10-8000000
---300.00-----300.00-50.00---33.33300.00-25.0066.67-20.00------
0.060.040.060.090.10.120.140.170.180.20.220.220.230.240.270.530.611.57000000
------------------------
Details

Keystats

ⓘ

Revenue and Growth

The INVO Bioscience Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the INVO Bioscience is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (k)INVENTORIES (k)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200620072008200920102011201220132014201520162017201820192020202120222023
                                   
0.0100.020.080.0100.010.020.020.490.150.030.211.2410.15.680.090.23
0030020101000009023010205080140.55
0010000000000000000
007060706050706070906040100270290260264.51
0070500000001060250200160280190622.29
0.0100.20.190.10.070.070.090.080.560.250.240.731.5510.556.30.621.26
000.040.030.020.020.010000.020.020.030.190.212.542.246.57
000000000000000.11.491.243.09
000000000000000000
0.020.040.070.060.060.040.040.030.030.020.020.020.010.060.090.1304.09
000000000000000005.88
0100000000000000000
0.020.050.110.090.080.060.050.030.030.020.040.040.040.250.44.163.4819.63
0.030.050.310.280.180.130.120.120.110.580.290.280.771.810.9510.464.120.89
                                   
000.010.010.010.010.010.010.010.010.010.010.020.020006
0.050.111.863.664.414.774.985.36.4912.0513.3113.6418.9820.1637.9846.248.852.71
-0.01-0.21-2.09-6.75-6.9-7.7-8.37-9.13-10.86-15.82-17.94-18.65-21.72-23.89-32.24-38.89-49.78-57.82
00-0.45-0.1600000000000000
000000000000000000
0.04-0.1-0.67-3.24-2.48-2.92-3.38-3.82-4.36-3.76-4.62-5-2.72-3.715.747.31-0.980.89
00.010.230.680.630.951.061.151.221.030.970.960.570.370.330.441.352.33
000.610.731.41.541.922.312.73.093.583.962.520.410.550.81.181.12
0001.910.170.080.04000000.020.720.720.010.123.26
05090210460490470470540220220210260000660880
00000000000013006900100629.92
00.060.933.532.663.063.493.934.464.344.775.133.51.52.291.253.418.22
00.090.0600000000.130.1300.350001.25
000000000000000000
00000000000003.652.921.91.6710.52
00.090.0600000000.130.13042.921.91.6711.78
00.150.993.532.663.063.493.934.464.344.95.263.55.55.213.155.0819.99
0.040.050.320.290.180.140.110.110.10.580.280.260.781.7910.9510.464.120.89
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of INVO Bioscience provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand INVO Bioscience's financial health and stability.

Assets

INVO Bioscience's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that INVO Bioscience must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of INVO Bioscience after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into INVO Bioscience's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (k)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20062007200820092010201120122013201420152016201720182019202020212022
00-1-40000-1-4-20-3-2-8-6-10
00000000000000000
00000000000000000
000000000000020-31
00030000141020442
00000000000000000
00000000000000000
00-1,00000000000001,000-4,000-6,000-6,000
00000000000000000
000000000000000-20
000000000000000-10
00000000000000000
00000000000000200
001000000000001140
001000000000001331
-----------------
00000000000000000
000000000000018-4-5
0-0.12-1.11-0.93-0.32-0.12-0.04-0.06-0.02-0.15-0.34-0.18-0.671.26-4.87-6.48-6.61
00000000000000000

INVO Bioscience stock margins

The INVO Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of INVO Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for INVO Bioscience.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the INVO Bioscience's sales revenue. A higher gross margin percentage indicates that the INVO Bioscience retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the INVO Bioscience's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the INVO Bioscience's total revenue generated. When comparing the revenue margin year over year, investors can gauge the INVO Bioscience's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the INVO Bioscience. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the INVO Bioscience's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

INVO Bioscience Margin History

INVO Bioscience Gross marginINVO Bioscience Profit marginINVO Bioscience EBIT marginINVO Bioscience Profit margin
2029e35.96 %0 %0 %
2028e35.96 %32.29 %0 %
2027e35.96 %22.95 %0 %
2026e35.96 %12.8 %0 %
2025e35.96 %-12.43 %0 %
2024e35.96 %-84.79 %-9.26 %
202335.96 %-224.03 %-266 %
202259.76 %-1,296.34 %-1,328.05 %
202196.63 %-125.48 %-159.86 %
202091.35 %-529.81 %-802.88 %
201990.54 %-120.95 %-146.62 %
201881.63 %-536.73 %-628.57 %
201782.14 %-228.57 %-250 %
201680 %-4,220 %-4,240 %
201535.96 %-6,000 %-49,600 %
201450 %-8,400 %-8,650 %
201366.67 %-2,033.33 %-2,533.33 %
201266.67 %-916.67 %-1,116.67 %
201171.43 %-1,000 %-1,142.86 %
201071.43 %-2,171.43 %-214.29 %
200933.33 %-3,066.67 %-7,766.67 %
200875 %-4,650 %-4,675 %
200735.96 %0 %0 %
200635.96 %0 %0 %

INVO Bioscience Stock Sales Revenue, EBIT, Earnings per Share

The INVO Bioscience earnings per share therefore indicates how much revenue INVO Bioscience has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue INVO Bioscience earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates INVO Bioscience's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of INVO Bioscience’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating INVO Bioscience's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

INVO Bioscience Revenue, EBIT and net profit per share

DateINVO Bioscience Sales per ShareINVO Bioscience EBIT per shareINVO Bioscience Earnings per Share
2029e32.41 undefined0 undefined0 undefined
2028e24.27 undefined0 undefined0 undefined
2027e17.11 undefined0 undefined0 undefined
2026e11.82 undefined0 undefined0 undefined
2025e5.47 undefined0 undefined0 undefined
2024e2.2 undefined0 undefined-0.2 undefined
20231.93 undefined-4.32 undefined-5.13 undefined
20221.34 undefined-17.43 undefined-17.85 undefined
20217.85 undefined-9.85 undefined-12.55 undefined
20203.85 undefined-20.41 undefined-30.93 undefined
20196.17 undefined-7.46 undefined-9.04 undefined
20182.13 undefined-11.43 undefined-13.39 undefined
20171.27 undefined-2.91 undefined-3.18 undefined
20160.23 undefined-9.59 undefined-9.64 undefined
20150.05 undefined-3 undefined-24.8 undefined
20140.11 undefined-9.33 undefined-9.61 undefined
20130.18 undefined-3.59 undefined-4.47 undefined
20120.43 undefined-3.93 undefined-4.79 undefined
20110.58 undefined-5.83 undefined-6.67 undefined
20100.7 undefined-15.2 undefined-1.5 undefined
20090.67 undefined-20.44 undefined-51.78 undefined
20080.67 undefined-31 undefined-31.17 undefined
20070 undefined-5.25 undefined-5.25 undefined
20060 undefined-0.17 undefined-0.17 undefined

INVO Bioscience business model

INVO Bioscience is one of the most popular companies on Eulerpool.com.

INVO Bioscience Revenue by Segment

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

INVO Bioscience Revenue by Segment

Segmente20232022202120202019
License---714,286 USD714,286 USD
Product Revenue---323,000 USD765,927 USD
License Revenue--3.57 M USD--
Clinic Revenue2.86 M USD614,854 USD43,745 USD--
Domestic Licensing & Distribution Fee---714,286 USD714,286 USD
Domestic Physicians---323,000 USD765,927 USD
Product Revenue--544,942 USD--
Product158,001 USD207,342 USD---

INVO Bioscience Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

INVO Bioscience historical P/E ratio, EBIT, and P/S ratio.

INVO Bioscience shares outstanding

The number of shares was INVO Bioscience in 2023 — This indicates how many shares 1.566 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue INVO Bioscience earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates INVO Bioscience's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of INVO Bioscience’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating INVO Bioscience's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

INVO Bioscience Stock splits

In INVO Bioscience's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for INVO Bioscience.

INVO Bioscience latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20230 -0.7  (0 %)2023 Q3
6/30/20230 -3.06  (0 %)2023 Q2
3/31/20230 -0.2  (0 %)2023 Q1
12/31/2022-3.88 -4.6  (-18.68 %)2022 Q4
9/30/2022-2.65 -4.2  (-58.37 %)2022 Q3
6/30/2022-4.9 -4.6  (6.05 %)2022 Q2
3/31/2022-5.1 -4.4  (13.73 %)2022 Q1
12/31/2021-0.23 -0.01  (94.77 %)2021 Q4
9/30/2021-0.2 -0.24  (-17.65 %)2021 Q3
6/30/2021-0.19 -0.17  (12.28 %)2021 Q2
1
2

INVO Bioscience list of shareholders

%
Name
Stocks
Change
Date
1.38256 % The Vanguard Group, Inc.54,05854,05812/31/2023
0.68609 % Geode Capital Management, L.L.C.26,82612,42012/31/2023
0.47632 % Sabby Management, LLC18,624-212,39912/31/2023
0.19082 % Goren (Andrea)7,461-2701/16/2024
0.18299 % UBS Financial Services, Inc.7,1557,15512/31/2023
0.15138 % Shum (Steve M)5,91901/16/2024
0.12647 % Tower Research Capital LLC4,9452,26212/31/2023
0.08716 % Campbell (Michael Jos)3,408-2701/16/2024
0.05013 % Szot (Matthew K)1,96001/16/2024
0.04302 % Davis (Trent Donald)1,68201/16/2024
1
2
3
4
...
5

INVO Bioscience Executives and Management Board

Mr. Andrea Goren55
INVO Bioscience Chief Financial Officer
Compensation 595,821
Mr. Steven Shum53
INVO Bioscience Chief Executive Officer, Director (since 2017)
Compensation 502,001
Mr. Michael Campbell65
INVO Bioscience Chief Operating Officer, Vice President - Business Development (since 2017)
Compensation 330,004
Mr. Matthew Szot49
INVO Bioscience Independent Director
Compensation 128,552
Mr. Trent Davis55
INVO Bioscience Independent Director
Compensation 106,113
1
2

Most common questions regarding INVO Bioscience

What is the P/E ratio of INVO Bioscience 2024?

The INVO Bioscience P/E ratio is -1.35.

What is the P/S ratio of INVO Bioscience 2024?

The INVO Bioscience P/S ratio is 0.13.

What is the AlleAktien quality score of INVO Bioscience?

The AlleAktien quality score for INVO Bioscience is 7/10.

What is the revenue of INVO Bioscience 2024?

The expected INVO Bioscience revenue is 8.61 M USD.

How high is the profit of INVO Bioscience 2024?

The expected INVO Bioscience profit is -797,640 USD.

What is the business model of INVO Bioscience

No history available for INVO Bioscience.

What is the INVO Bioscience dividend?

INVO Bioscience pays a dividend of 0 USD distributed over payouts per year.

How often does INVO Bioscience pay dividends?

The dividend cannot currently be calculated for INVO Bioscience or the company does not pay out a dividend.

What is the INVO Bioscience ISIN?

The ISIN of INVO Bioscience is US44984F4019.

What is the INVO Bioscience ticker?

The ticker of INVO Bioscience is INVO.

How much dividend does INVO Bioscience pay?

Over the past 12 months, INVO Bioscience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, INVO Bioscience is expected to pay a dividend of 0 USD.

What is the dividend yield of INVO Bioscience?

The current dividend yield of INVO Bioscience is .

When does INVO Bioscience pay dividends?

INVO Bioscience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of INVO Bioscience?

INVO Bioscience paid dividends every year for the past 0 years.

What is the dividend of INVO Bioscience?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is INVO Bioscience located?

INVO Bioscience is assigned to the 'Health' sector.

Wann musste ich die Aktien von INVO Bioscience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of INVO Bioscience from 9/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did INVO Bioscience pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of INVO Bioscience in the year 2023?

In the year 2023, INVO Bioscience distributed 0 USD as dividends.

In which currency does INVO Bioscience pay out the dividend?

The dividends of INVO Bioscience are distributed in USD.

All fundamentals about INVO Bioscience

Our stock analysis for INVO Bioscience Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of INVO Bioscience Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.